Do Prostate Cancer Patients Not at High Risk Need Long-Term Hormone Therapy With Radiation?
Hormone Deprivation Unnecessary With High-Dose Radiation, Fox Chase Cancer Center Study Finds
ATLANTA -- Men with prostate cancer who do not have a high risk of recurrence or disease progression do not need to have long-term hormone therapy in addition to external-beam radiation therapy if they receive high radiation doses. That is the finding of a Fox Chase Cancer Center study presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.
"Several large randomized clinical trials have shown that patients with high-risk disease may live longer if they have long-term androgen deprivation in addition to radiation therapy," said the study's lead author, Fox Chase radiation oncologist Shelly B. Hayes, M.D. Features of high-risk disease include a Gleason score of 8 to 10, stage T3 to T4 cancer and/or a PSA level greater than 30.
"The purpose of our study was to determine if certain patients with less aggressive disease might be treated inadequately with radiation alone and would benefit from the addition of hormone therapy," Hayes said. "It turns out that radiation dose is the critical factor and additional treatment is unnecessary."
The researchers analyzed treatment and outcomes of 496 men treated with three-dimensional conformal radiation therapy during the 10-year period between 1991 and 2001. The group that did best included patients with Gleason scores of 2 to 6 who received doses equal to or greater than 72 Gy or patients with a Gleason score of 7 who received doses equal to or greater than 76 Gy. (A Gy or "gray" dose is a measure of the radiation absorbed by the targeted organ.)
In contrast, patients with the worst treatment outcomes were those with a Gleason score of 7 who received less than 76 Gy and those with a PSA level greater than 10 who received less than 72 Gy of radiation.
The Fox Chase researchers concluded that patients with intermediate-risk prostate cancer do not need long-term androgen deprivation if they receive high-dose radiation-greater than 76 Gy.
Along with Hayes, study authors included statistician Alexandra L. Hanlon, Ph.D., radiation oncologist Eric M. Horwitz, M.D., radiation oncology chairman Alan Pollack, M.D., Ph.D., urologic oncologist Robert G. Uzzo, M.D., and radiation oncologist Steven J. Feigenberg, M.D.
Fox Chase Cancer Center was founded in 1904 in Philadelphia as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.